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Risk Factors for Recurrence of Clostridium difficile Infection: 
Effect of Vancomycin-resistant Enterococci Colonization
Recurrent Clostridium difficile infection (CDI) is one of the most difficult problems in 
healthcare infection control. We evaluated the risk factors associated with recurrence in 
patients with CDI. A retrospective cohort study of 84 patients with CDI from December 
2008 through October 2010 was performed at Pusan National University Yangsan Hospital. 
Recurrence occurred in 13.1% (11/84) of the cases and in-hospital mortality rate was 7.1% 
(6/84). Stool colonization with vancomycin-resistant enterococci (VRE) (P = 0.006), 
exposure to more than 3 antibiotics (P = 0.009), low hemoglobin levels (P = 0.025) and 
continued use of previous antibiotics (P = 0.05) were found to be more frequent in the 
recurrent group. Multivariate analysis indicated that, stool VRE colonization was 
independently associated with CDI recurrence (odds ratio, 14.519; 95% confidence 
interval, 1.157-182.229; P = 0.038). This result suggests that stool VRE colonization is a 
significant risk factor for CDI recurrence.
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INTRODUCTION 
Clostridium difficile infection (CDI) is one of the leading causes 
of nosocomial illness, and the incidence and severity of CDI have 
increased since 2000 (1). Most patients with CDI respond well 
to medical therapy including withdrawal of antibiotics and treat-
ment with metronidazole or vancomycin. However, up to 30% 
of patients experience CDI recurrence (2). We retrospectively 
studied a cohort of patients with CDI at our institution and iden-
tified risk factors associated with recurrence. The purpose of 
this study was to identify patients at risk for recurrent CDI who 
may benefit from early preventive measures and therapeutic 
interventions.
MATERIALS AND METHODS
Identification of subjects and data collection
This retrospective study was performed at Pusan National Uni-
versity Yangsan Hospital, a 700-bed teaching hospital, between 
December 2008 and October 2010. All medical records were re-
viewed for patients who had been tested by analysis of stool cul-
tures or toxin assays. In addition, all patients diagnosed with CDI, 
pseudomembranous colitis, or diarrhea were reviewed. 
  The exclusion criteria applied were: age of < 15 yr, failure to 
follow-up before completion of CDI treatment, presence of any 
other cause of diarrhea (such as laxative use), presence of any 
other diarrhea-causing pathogens, and inflammatory bowel 
disease.
  Clinical data, including demographic information, comorbid-
ities, prior therapeutic interventions (history of abdominal sur-
gery within a month before CDI diagnosis, mechanical ventila-
tion, or tube feeding before or during the treatment of CDI), re-
cent medications within 30 days of diagnosis of CDI, the num-
ber and type of antibiotics prescribed before diagnosis of CDI, 
laboratory parameters, acid suppressive therapy, concurrent 
use of probiotics, therapy prescribed for CDI (discontinuation 
of antibiotics within 3 days of CDI diagnosis, metronidazole or 
oral vancomycin), and clinical outcomes were obtained from 
medical records. After excluding mortality cases, patients were 
classified into a recurrent group and non-recurrent group, based 
on recurrence within 60 days of cure. 
Definitions
The diagnosis of CDI should include the following findings: 1) 
the presence of diarrhea, defined as passage of 3 or more un-
formed stools within 24 or fewer consecutive hours; and 2) a 
positive stool test result for the presence of toxigenic C. difficile 
or its toxins or colonoscopic or histopathological confirmation 
of pseudomembranous colitis (1). CDI was categorized accord-
ing to the SHEA/IDSA guidelines (1): 1) healthcare facility (HCF)-
onset HCF-associated CDI; 2) community-onset HCF-associat-
ed CDI; and 3) community-associated CDI. A score developed Choi HK, et al.  •  VRE Colonization and CDI Recurrence 
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by Charlson et al. (3), was used to evaluate the prognosis based 
on age and comorbidities. CDI was considered severe if one of 
the following factors was found to be present: 1) leukocytosis 
with a white blood cell count of  ≥ 15,000 cells/μL; or 2) a serum 
creatinine level of  ≥ 1.5 times the premorbid level (1). Patients 
were regarded as cured when stool frequencies and consisten-
cies were normal for at least 3 consecutive days. Recurrence was 
defined as the reappearance of either a symptom or a positive 
toxin assay within 60 days of the treatment. Treatment with pro-
ton pump inhibitors (PPIs) or histamine H2-blockers was de-
fined as at least 3 days of treatment before the development of 
CDI, and continuous use thereafter. CDI-related mortality was 
defined as death that occurred during the treatment period with 
concurrent signs of CDI. 
 
Statistical analysis
All data are presented as median and range. Comparisons be-
tween groups were performed using the Fisher exact test for cat-
egorical variables and the Mann-Whitney U-test for continuous 
variables. The relative risk of recurrence was calculated using a 
multivariate logistic regression. We simultaneously entered po-
tential confounding variables with a P value of less than 0.1 in 
the univariate analysis in the final regression model. For all anal-
yses, a P value less than 0.05 was considered statistically signifi-
cant. Statistical analysis was performed using SPSS version 10.0 
(SPSS Inc., Chicago, IL, USA).
Ethics statement 
This study was approved by the institutional review board of 
Pusan National University Yangsan Hospital (IRB approval num-
ber: 2010-068). Informed consent was waived by the board. 
RESULTS
Demographic characteristics, clinical characteristics, and 
clinical course in patients with CDI
A total of 84 patients with CDI were identified during the study 
period: 59 (70.2%) were HCF-onset HCF-associated infections; 
19 (22.6%), community-onset HCF-associated infections; and 6 
(7.1%), community-associated infections (Table 1). The median 
age of the patients was 62.5 yr (range, 15-84). Forty-four patients 
were male and 40 were female. The median duration of hospi-
talization before the diagnosis of CDI was 10 days (range, 0-198) 
and 14 days (range, 2-198) in HCF-onset cases.
  Seventy-two patients (85.7%) were treated with antibiotics. 
The most common antibiotics administered before diagnosis of 
CDI were third-generation cephalosporins (39.3%) and fluoro-
quinolones (39.3%) (Table 2). The main causes of previous anti-
Table 1. Demographic and clinical characteristics of the patients with and without recurrence of Clostridium difficile infection
Characteristics All patients (n = 84) Recurrent group (n = 11) Non-recurrent group (n = 67)    P value
Classification 
   HCF-onset HCF-associated
   Community-onset HCF-associated
   Community-associated 
 
59 (70.2)
19 (22.6)
6 (7.1)
 
9 (81.8)
1 (9.1)
1 (9.1)
 
47 (70.1)
15 (22.4)
5 (7.5)
 
 
 
 
Age, year, median (range) 62.5 (15-84) 60 (15-82) 62 (17-84) 0.813
Sex, male 44 (52.4) 7 (63.6) 34 (50.7) 0.524
Underlying disease
   Malignancy  
   Diabetes 
   Chronic kidney disease/dialysis
   Liver cirrhosis
   Neurologic disease
   Pulmonary disease
 
16 (19)
19 (22.6)
9 (10.7)
4 (4)
33 (39.3)
5 (6)
 
2 (18.2)
2 (18.2)
1 (9.1)
0 (0)
3 (27.3)
2 (18.2)
 
11 (16.4)
16 (23.9)
6 (9.0)
4 (6)
26 (38.8)
2 (3)
 
1.0
1.0
1.0
1.0
0.524
0.093
Charlson comorbidity index, median (range) 2 (0-8) 3 (0-7) 2 (0-7) 0.214
Length of stay before CDI diagnosis, day; median (range) 10 (0-198) 12.5 (0-77) 8 (0-198) 0.355
Recent therapeutic intervention
   Abdominal surgery
   Mechanical ventilation
   Tube feeding
   Total parenteral nutrition 
 
5 (6)
9 (10.7)
19 (22.6)
6 (7.1)
 
0 (0)
2 (18.2)
4 (36.4)
0 (0)
 
5 (7.5)
6 (9)
13 (19.4)
5 (7.5)
 
1.0
0.314
0.242
1.0
Recent medications
   Antimicrobial therapy
   Chemotherapy 
   Immunosuppressive agent
 
72 (85.7)
8 (9.5)
3 (3.6)
 
10 (90.9)
3 (27.3)
0 (0)
 
57 (85.1)
4 (6)
3 (4.5)
 
1.0
0.054
1.0
Gastric acid suppression
   Proton pump inhibitors
   Histamine H2-blockers
36 (42.9)
15 (17.9)
25 (29.8)
6 (54.5)
2 (18.2)
4 (36.4)
27 (40.3)
11 (16.4)
18 (26.9)
0.513
1.0
0.374
Probiotics  36 (42.9) 7 (63.6) 27 (40.3) 0.195
Preexisting stool VRE colonization 8 (9.5) 4 (36.4) 3 (4.5) 0.006
Data are presented as number (%) of patients unless otherwise specified. HCF, healthcare facility; CDI, Clostridium difficile infection; VRE, vancomycin-resistant enterococci.Choi HK, et al.  •  VRE Colonization and CDI Recurrence 
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biotic prescription were pneumonia (28.6%), intra-abdominal 
infection (13.1%), and urinary tract infection (10.7%). 
  Stool vancomycin-resistant enterococci (VRE) colonization 
was identified in 8 patients (9.5%) at the time of treatment initi-
ation. Among the recurrent group, 1 patient’s baseline culture 
was negative for VRE, and new detection of VRE stool coloniza-
tion was identified after completion of antimicrobial therapy 
for CDI. We considered this new detection case as a preexisting 
VRE negative. No VRE infections occurred in any of the patients 
during the treatment and follow-up. 
  The in-hospital mortality rate was 7.1% (6/84), and none of 
these cases was related to CDI. Eleven patients (13.1%) experi-
enced recurrence (recurrent group) within 60 days of cure, and 
67 (79.8%) did not experience recurrence (non-recurrent group). 
Treatment, complications, and outcomes of CDI 
Fourteen patients (16.7%) were not treated due to a self-limiting 
course (Table 3). Metronidazole was the initial therapeutic regi-
men for the remaining 70 patients (83.3%). Oral vancomycin 
was substituted thereafter for 2 patients because of unsatisfac-
tory responses to metronidazole therapy. Only 3 patients (27.3%) 
were able to stop using previous non-C. difficile antibiotics in 
the recurrent group, while 41 patients (61.2%) stopped antibiot-
ics after CDI diagnosis in the non-recurrent group (P = 0.05). 
  Three patients were treated at an outpatient clinic. Among 
the hospitalized patients, the median hospital stay was 28 days 
(range, 1-350 days). The recurrent group required prolonged 
hospitalization during first CDI episode (median 77.5 days vs 
22 days; P = 0.002). The 2 study groups were similar in terms of 
the time lag for recovery, CDI severity and complications such 
as acute kidney injury or shock.
Table 2. Number and type of antimicrobial agents used before diagnosis of Clostridi-
um difficile infection and the conditions for which the treatment was indicated
Antimicrobial agents used 
All  
patients  
(n = 84) 
Recurrent 
group 
 (n = 11) 
Non- 
recurrent 
group (n = 67)
P 
value
Number of antibiotics used
   0 
   1 
   2 
   3 
   ≥ 4 
   < 3 
   ≥ 3 
10 (11.9)
23 (27.4)
27 (32.1)
13 (15.5)
11 (13.1)
60 (71.4)
24 (28.6)
0 (0)
3 (27.3)
1 (9.1)
4 (36.4)
3 (27.3)
4 (36.4)
7 (63.6)
9 (13.4)
17 (25.4)
26 (38.8)
8 (11.9)
7 (10.5)
52 (77.6)
15 (22.4)
 
 
 
 
 
0.009
 
Type of antibiotics
   1st cephalosporin 
   2nd cephalosporin
   3rd cephalosporin 
   4th cephalosporin
   Penicillin/β-lactamase 
      inhibitor 
   Fluoroquinolone
   Glycopeptide 
   Carbapenem 
   Macrolide 
   Aminoglycoside 
   Clindamycin 
   Monobactam 
   Antimycobacterial  
      agents
   Antiviral agents
   Others
 
4 (4.8)
9 (10.7)
33 (39.3)
8 (9.5)
21 (25)
33 (39.3)
12 (14.3)
8 (9.5)
4 (4.8)
8 (9.5)
6 (7.1)
7 (8.3)
4 (4.8)
2 (2.4)
6 (7.1)
 
1 (9.1)
0 (0)
3 (27.3)
2 (18.2)
6 (54.5)
6 (54.5)
2 (18.2)
2 (18.2)
1 (9.1)
1 (9.1)
2 (18.2)
0 (0)
2 (18.2)
0 (0)
2 (18.2)
 
3 (4.5)
9 (13.4)
27 (40.3)
5 (7.5)
15 (22.4)
24 (35.8)
9 (13.4)
5 (7.5)
3 (4.5)
6 (9)
4 (6)
7 (10.4)
2 (3)
2 (3)
4 (6)
 
0.463
0.344
0.516
0.255
0.06
0.319
0.649
0.255
0.463
1.0
0.198
0.584
0.093
1.0
0.198
Reason for antibiotics use
   Pneumonia 
   Urinary tract infection
   Skin and soft tissue 
      infection
   Intraabdominal infection
   Others 
   Prophylaxis 
   Unknown 
 
24 (28.6)
9 (10.7)
7 (8.3)
11 (13.1)
5 (6)
7 (8.3)
12 (14.3)
 
6 (54.5)
1 (9.1)
1 (9.1)
1 (9.1)
0 (0)
0 (0)
2 (18.2)
 
16 (23.9)
6 (9)
6 (9)
10 (14.9)
5 (7.5)
6 (9)
10 (14.9)
 
0.065
1.0
1.0
1.0
1.0
0.586
0.675
Data are presented as number (%) of patients. 
Table 3. Laboratory parameters, treatment, and clinical outcome for Clostridium difficile infection
Parameters All patients (n = 84)  Recurrent group (n = 11) Non-recurrent group (n = 67) P value
Laboratory data at diagnosis
   WBC count (/µL)
   Hb (g/dL)
   Platelet count (× 10
3/µL)
   Creatinine (mg/dL)
   CRP (mg/dL) 
   Albumin (g/dL) 
 
11,600 (350-49,950)
11 (7-14.9)
243 (27-680)
0.9 (0.52-8.13)
4.88 (0.01-41.85)
3.3 (2.3-4.5)
 
11,725 (350-24,920)
9.4 (7.6-12.4)
236.5 (27-433)
1.11 (0.56-3.5)
8.06 (0.28-35.24)
3.25 (2.4-4.0)
 
11,565 (1,400-49,950)
11.15 (7.8-14.9)
232 (28-680)
0.87 (0.52-8.13)
4.48 (0.01-41.85)
3.4 (2.3-4.5)
 
0.959
0.025
0.982
0.585
0.144
0.225
CDI treatment  
   No treatment 
   Metronidazole only 
   Switch to vancomycin 
   Quit previous antibiotics 
   Time to CDI treatment, days
 
14 (16.7)
68 (81)
2 (2.4)
44 (52.4)
3 (0-50)
 
0 (0)
11 (100)
0 (0)
3 (27.3)
3 (1-50)
 
14 (20.9)
51 (76.1)
2 (3)
41 (61.2)
3 (0-19)
 
0.198
0.198
1.0
0.05
0.681
Clinical outcome
   Time to recovery, days
   Severe CDI 
   Shock 
   Acute kidney injury 
   Duration of hospitalization, days  
      (outpatient excluded)
 
4 (1-40)
9 (10.7)
6 (7.1)
11 (13.1)
28 (1-350)
 
5 (2-40)
1 (9.1)
1 (9.1)
3 (27.3)
77.5 (20-163)
 
4 (1-18)
6 (9)
2 (3)
5 (7.5)
22 (1-350)
 
0.253
1.0
0.37
0.08
0.002
Data are presented as number (%) of patients or median (range). WBC, white blood cell count; Hb, hemoglobin; CRP, C-reactive protein; CDI, Clostridium difficile infection.Choi HK, et al.  •  VRE Colonization and CDI Recurrence 
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Risk factors for recurrence of CDI
There was no significant difference in age, gender, comorbidity, 
recent therapeutic interventions and medications between the 
2 groups (Table 1). Even though statistically significant differ-
ences were not observed, more patients of the recurrent group 
had underlying pulmonary disease (18.2% vs 3%, P = 0.093) and 
chemotherapy history (27.3% vs 6%, P = 0.054) as compared to 
the non-recurrent group. The length of stay before CDI diagno-
sis, tube feeding, gastric acid suppression, and concurrent use 
of probiotics were not found to be significantly associated with 
recurrence. The patients with CDI recurrence had greater prev-
alence of preexisting stool VRE colonization (36.4% vs 4.5%, P = 
0.006). 
  With regard to antimicrobial therapy, patients who received 
more than 3 antibiotics were more common in the recurrent 
group as compared to the non-recurrent group (63.6% vs 22.4%, 
P = 0.009) (Table 2). In contrast to a previous study (4), fluoro-
quinolone exposure was found to be not significantly different 
between the 2 groups. Patients treated for pneumonia were more 
commonly found in the recurrent group as compared to the non-
recurrent group (54.5% vs 23.9%, P = 0.065), although this ob-
servation was not statistically significant. 
  The white blood cell count, the levels of serum albumin, and 
the levels of C-reactive protein at diagnosis were not significant-
ly different between the 2 groups. However, the hemoglobin level 
was significantly low in the recurrent group (P = 0.025) (Table 3). 
  Multivariate analysis showed that stool VRE colonization (odds 
ratio [OR], 14.519; 95% confidence interval [CI], 1.157-182.229; 
P = 0.038) was the only independent and significant risk factor 
for CDI recurrence (Table 4). 
DISCUSSION
Despite an initial successful response, CDI recurs in 15%-30% 
of the cases (2). Recurrence typically occurs within 1 to 3 weeks 
after completion of treatment, but late recurrences of up to 2 
months are not infrequent (2, 5, 6). In this study, 13.1% of pa-
Table 4. Multivariate analysis of risk factors for recurrence of Clostridium difficile in-
fection 
Risk factors Odds ratio  95% CI P value
Pulmonary disease   4.332 0.074-252.610 0.480
Chemotherapy    6.733 0.465-97.455 0.162
≥ 3 antibiotics exposure    1.384 0.133-14.414 0.786
Pneumonia    1.412 0.119-16.760 0.785
Penicillin/β-lactamase inhibitor   4.003 0.440-36.446 0.218
Antimycobacterial agent 17.672 0.538-580.506 0.107
Anemia (Hb < 11 mg/dL)   4.013 0.449-35.890 0.214
Continuing previous antibiotics   2.583 0.383-17.398 0.329
Previous VRE colonization  14.519 1.157-182.229 0.038
Acute kidney injury   5.602 0.475-66.051 0.171
Duration of hospitalization, days   1.006 0.990-1.022 0.493
Hb hemoglobin; VRE, vancomycin resistant enterococci.
tients experienced recurrence within 60 days. This rate is lower 
than those in other Western studies, but is higher than those in 
previous Korean reports (1.2%-12%) (7-9). 
  Risk factors for recurrent CDI described in previous studies 
include old age (6, 10, 11), low serum albumin level (11), poor 
quality-of-health index (6), fecal incontinence (12), lower levels 
of immunoglobulin against toxin B or toxin A (13, 14), infection 
with the B1/NAP1/027 strain (14), hospital-acquired disease (15), 
history of surgery (16), concomitant treatment with antacid med-
ication (10-12), continued treatment with non-C. difficile anti-
biotics after CDI (5, 10), and fluoroquinolone use (4). These stud-
ies did not identify an association between stool VRE coloniza-
tion and recurrent CDI. To the best of our knowledge, the pres-
ent study is the first investigation of the effect of stool VRE colo-
nization on the recurrence of CDI. Interestingly, stool VRE colo-
nization was found to be the only reliable risk factor for recur-
rence of CDI. Our results suggest a link between colonization of 
stool with VRE and recurrent CDI.
  VRE-colonized patients with CDI have an increased risk of 
skin contamination and environmental shedding of VRE (17-19). 
In previous reports (18, 19), VRE colonized patients with diar-
rhea have an increased prevalence of environmental VRE con-
tamination. Moreover, Sethi et al. (17) showed that treatment of 
CDI with metronidazole or vancomycin may promote transmis-
sion of VRE, by promoting persistent high-density colonization 
of VRE. It is interesting to note that shedding of VRE remained 
common even after diarrhea was resolved (17). Therefore, pa-
tients with stool colonization of VRE require careful medical su-
pervision if they exhibit CDI symptoms such as diarrhea. There 
is a concern that oral vancomycin may be more likely to promote 
acquisition and overgrowth of VRE (20, 21). Because multiple 
genes are necessary to generate vancomycin resistance in en-
terococci, acquisition of VRE colonization does not occur via 
mutations in the susceptible enterococci in the intestinal tract. 
Rather, selective pressure exerted by oral vancomycin may facil-
itate the exogenous acquisition of VRE or the transfer of vanco-
mycin resistance genes from other organisms to the enterococci 
in the intestinal tract (22, 23). However, several studies have failed 
to identify an increased risk of VRE emergence in patients treat-
ed with oral vancomycin (21, 24, 25). Similarly, newly detected 
VRE colonization was found to be uncommon in this study (with 
only a single case observed). It should be noted that we did not 
routinely monitor stool VRE colonization after recovery from 
CDI. 
  In this study, it appears that patients colonized with VRE may 
be at an increased risk for CDI recurrence. We cannot conclu-
sively state that stool VRE colonization is responsible for the re-
currence of CDI because many patients of the recurrent group 
had multiple severe coexisting conditions. C. difficile and VRE 
have emerged as major nosocomial pathogens that require rig-
orous monitoring and control. VRE and C. difficile share risk Choi HK, et al.  •  VRE Colonization and CDI Recurrence 
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factors and putative causes, such as antimicrobial therapy and 
prolonged hospitalization (26). Stool VRE colonization may rep-
resent the final consequence of several CDI risk factors. How-
ever, VRE colonization has remained a significant risk factor af-
ter adjusting for confounding variables such as the number of 
antibiotics and duration of hospitalization in this study. Our re-
sults suggest that gastrointestinal bacterial colonization plays an 
important role in the development of recurrent CDI. Although 
the pathogenesis of CDI recurrence is poorly understood, it has 
been proposed to involve alterations of constituents of normal 
bowel flora (27, 28). We cautiously propose that patients with 
stool VRE colonization are more prone to experience alterations 
of the bowel flora after CDI. 
  This study has several limitations. First, this is a single center 
study with a relatively small number of patients. Second, we 
could not evaluate the effect of the initial regimen on CDI recur-
rence. Studies have shown that the rates of treatment failure and 
recurrence are greater for patients initially treated with metro-
nidazole than for patients initially treated with vancomycin (29). 
Except for the untreated patients, all patients in this study were 
initially treated with metronidazole. Two patients whose treat-
ment was switched to vancomycin did not experience recur-
rence. Therefore, we cannot evaluate the effect of the initial treat-
ment regimen in this study. Third, we were unable to perform 
ribotyping of stool C. difficile isolates. Therefore, we could not 
differentiate between reinfection and recurrence. In addition, 
we cannot rule out the possibility that the B1/NAP/027 strain 
existed in our cohort. The first case of isolation of C. difficile PCR 
ribotype 027 in Korea was recently reported in a patient with re-
fractory CDI (30). Finally, this study may be affected by all of the 
limitations of a retrospective design. Further prospective studies 
may be needed to provide further confirmation of our results. 
Although the results do not allow us to conclude that stool VRE 
colonization increases CDI recurrence, further prospective stud-
ies with a larger number of patients should be performed to val-
idate this relationship and the pathophysiology between VRE 
colonization and recurrent CDI. 
  In conclusion, stool VRE colonization appears to be an inde-
pendent risk factor for CDI recurrence. Preventing initial acqui-
sition of VRE and C. difficile, both in terms of VRE and CDI con-
trol, should be emphasized. 
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